Eugenia Gianos, MD
Cardiovascular Disease · New York, NYNPI 1689726630
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.8%), consulting fees and education — rather than concentrated in one kind of arrangement. Kaneka Medical America LLC accounts for 64.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $2,031 and has fallen 79.9% since, to $408 in 2025.
Across 19 payments — averaging $245.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaneka Medical America LLC$3K
- Esperion Therapeutics, Inc.$281
- Regeneron Healthcare Solutions, Inc.$225
- Boston Scientific$224
- Boehringer Ingelheim$223
- Novo Nordisk$206
- plus $513 from 5 others
Across 46 payments — averaging $13,339 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$245K
- Eli Lilly$195K
- Novartis$172K
- Esperion Therapeutics, Inc.$1K
What the payments were for
- Consulting fees$1,50032%
- Food & beverage$1,67236%
- Education$1,50032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaneka Medical America LLC | 2 | $3,000 |
| Esperion Therapeutics, Inc. | 3 | $281 |
| Regeneron Healthcare Solutions, Inc. | 2 | $225 |
| Boston Scientific | 2 | $224 |
| Boehringer Ingelheim | 1 | $223 |
| Novo Nordisk | 1 | $206 |
| Cleerly, Inc. | 1 | $180 |
| Amgen | 4 | $161 |
| Abbott | 1 | $110 |
| Cardiva Medical, Inc. | 1 | $44 |
| Regeneron | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,672 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 28 | $41,662 |
| JardianceEmpagliflozin | 22 | $24,300 |
| EliquisApixaban | 24 | $18,850 |
| Ezetimibe | 84 | $1,775 |
| Rosuvastatin Calcium | 112 | $1,487 |
| Metoprolol Succinate | 57 | $760 |
| Atorvastatin Calcium | 74 | $745 |
| Telmisartan | 18 | $698 |
| Amlodipine Besylate | 48 | $393 |
| Carvedilol | 22 | $280 |
| Losartan Potassium | 16 | $190 |
| ClopidogrelClopidogrel Bisulfate | 14 | $164 |
| Lisinopril | 15 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $223 | $24,30022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.